Why analysis of variance is inappropriate for multiclinic trials.
Violations of the assumptions behind analysis of variance (ANOVA) models do not tend to affect the alpha-level but can greatly decrease the power of a clinical trial to detect treatment effects. The very nature of multiclinic studies guarantees the violation of some of these assumptions. In this article, I explore the reduction in power that results from two of these violations--heterogeneity of variance across sites and the existence of "floor" and "ceiling" effects. I propose other methods of statistical analysis that avoid this loss of power.